Efficacy of 7 Days Versus 14 Days of Antibiotic Therapy for Acute Pyelonephritis in Kidney Transplant Recipients, a Multicentre Randomized Non-inferiority Trial.
Recruiting now · Phase 3
Conditions studied: Pyelonephritis Acute, Kidney Transplant Infection
In brief
Infections are a major cause of morbidity and mortality in solid organ transplant recipients. In kidney transplant recipients (KTR) urinary tract infection (UTI) represent 45-72% of all infections, and 30% of all hospitalizations for sepsis. Acute transplant pyelonephritis are the most common complications occurring in more than 20% of patients, mainly in the first year after transplantation. They are associated with an increased risk of acute kidney rejection and long-term kidney graft dysfunction. Gram-negative bacteria, mainly E. coli, account for more than 70% of UTI in KTR. As those infections are favoured by urinary tract modifications/defects and immunosuppression, they are often recurrent and necessitate repeated courses of antibiotics. Selective pressure due to antibiotic consumption, along with frequent hospital admissions and immunosuppression, are well known risk factors for the development of antibiotic resistant infections. Multidrug (MDR)- or extensively (XDR)- drug resistant Enterobacteriaceae including ESBL- or carbapenemase-producing organisms, are thus increasingly observed in transplant units and represent a global threat as very few new antibiotics are expected in the next decade. One main strategy to limit antimicrobial resistance is to reduce the duration of antibiotic treatment. A 7 day-course is recommended for simple acute pyelonephritis (APN) treated with fluoroquinolones or parenteral B-lactams, prolonged up to 10 or 14 days in the presence of underlying disease at risk of complications. Most KT teams treat patients between 14-21 days as recommended by American guidelines. However, the need to extend treatment duration in immunosuppressed patients is a poorly defined concept and the optimal duration of treatment for APN in KTR is not known as these patients are excluded from most studies. As there is an urgent need to reduce antibiotic consumption in this population at high risk of developing infections due to resistant pathogens, the hypothesis is that a 7 day-treatment is sufficient to cure APN with good clinical response after 48h of treatment in KTR and is as effective as 14 days.
Key facts
- Study ID
- NCT05597540
- Run by
- Assistance Publique - Hôpitaux de Paris
- People needed
- 470
- Starts
- 2024-02-22
- Expected to finish
- 2027-08-22
- Last updated by the study team
- 2024-05-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age >18 years KTR
- APN defined by: fever (T°≥38°C) (with or without clinical signs and/or symptoms of UTI) and pyuria (≥10\^4 white blood cells/mL or ≥10/mm3) and positive urine culture (uropathogen ≥10\^3 CFU/mL susceptible to the empirically administrated antibiotic)
- No confirmed or suspected febrile non urinary bacterial infection
- No urologic/renal complication at baseline imaging (abscess, obstruction...)
- Favourable early response to antibiotic treatment:48 to 60 hours after the first dose of antibiotic effective against the causative uropathogen) defined by: T°<38°C and improvement (or resolution) of signs and/or symptoms of urinary tract infection if present at diagnosis
- Written informed consent
You may not qualify if…
- Severe or complicated condition
- Any rapidly progressing disease or immediately life-threatening illness, including, but not limited to, septic shock, current or impeding respiratory failure, acute heart or liver failure
- Admission or stay in intensive care unit at baseline
- Obstruction of the urinary tract
- Renal, perinephric or prostatic abscess
- Prior inclusion in this study
- Current participation to another interventional study
- Dual antibiotic therapy (prophylactic antibiotic such as cotrimoxazole allowed) (only 1 dose of aminoside is allowed before randomization)
- First month post transplantation
- Current indwelling catheter (including bladder catheter, ureteral stents, percutaneous nephrostomy tubes)
- Neurogenic bladder
- Enterocystoplasty
- Immunodeficiency or immunosuppressive therapy not related to kidney transplantation including hematologic malignancy, cancer, asplenia, neutropenia<500 neutrophils/mm3
- Pregnancy, breastfeeding
- Hypersensitivity or previous severe adverse drug reaction to the antibiotic therapy
- Unable or unwilling, in the judgment of the investigator, to comply with the protocol
- Life expectancy<1 month
- Patient under legal guardianship or without healthcare coverage
- Homeless patient
- Women with childbearing potential not using adequate contraception
Where it is running
- CHU Mondor — Créteil, France (enrolling)
- CHU Necker — Paris, France (enrolling)
- CHU Saint Louis — Paris, France (enrolling)
- CHU Nantes — Nantes, France (enrolling)
- CHU Bordeaux — Bordeaux, France
- CHU Toulouse — Toulouse, France
- Hôpital Foch — Boulogne-Billancourt, France
- CHU Lyon — Lyon, France
- CHU Kremlin-Bicêtre — Paris, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.